Form 8-K Revance Therapeutics, For: Nov 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Revance Therapeutics (RVNC) Misses Q3 EPS by 92c; Offers Guidance
November 8, 2023 4:50 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.63), $0.92 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $56.8 million versus the consensus estimate of $59.29 million.
In September 2023, Revance revised its 2023 GAAP and Non-GAAP operating expense guidance to reflect... More
